CCXI
ChemoCentryx Inc is a biopharmaceutical company. It is engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.
Churchill Capital Corp XI (CCXI) is rated C (2.3/5) on Deltasharpe Prism, scored against Financial Services sector peers. Its strongest pillar is Momentum (C+); its weakest is Profitability (D). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-04 | C+ (2.5) | C+ (2.5) | D (1.5) | C+ (2.6) | C+ (2.5) | C (2.3) |
| 2026-10-28 | C+ (2.5) | C+ (2.5) | D (1.5) | C+ (2.6) | C+ (2.5) | C (2.3) |
| 2026-10-21 | C+ (2.5) | C+ (2.5) | D (1.5) | B- (3.0) | C+ (2.5) | C (2.4) |
| 2026-10-14 | C+ (2.5) | C+ (2.5) | D (1.5) | C (2.5) | C+ (2.5) | C (2.3) |
| 2026-10-07 | C+ (2.5) | C+ (2.5) | D (1.5) | B- (3.0) | C+ (2.6) | C (2.4) |